FindTrial
Sign In

IP3R Modulation by Cancer Genes in Mesothelioma

IP3R Modulation by Cancer Genes Bcl-2 & PKM2 in Mesothelioma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03558932
Enrollment
20
Registered
2018-06-15
Start date
2019-01-31
Completion date
2024-06-30
Last updated
2018-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Mesothelioma

Brief summary

Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction

Interventions

DIAGNOSTIC_TESTpleural biopsy

diagnostic sampling

Sponsors

KU Leuven
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* suspicion of mesothelioma * referral for diagnostic thoracoscopy

Exclusion criteria

* contra-indication for thoracoscopy

Design outcomes

Primary

MeasureTime frameDescription
Pleural biopsy5 yearsBiopsy

Other

MeasureTime frameDescription
Immunoblotting5 yearsbiopsy
Cytometric analysis (FACS-based approaches)5 yearsbiopsy
Live cell imaging for Ca2+-signaling5 yearsbiopsy

Contacts

Primary ContactJonas Yserbyt
jonas.yserbyt@uzleuven.be+32 16 34 68 01

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026